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Disposition of Mefloquine and Enpiroline Is Highly Influenced by a
Chronic Schistosoma mansoni Infection
Katrin Ingram,a,b Urs Duthaler,a,b Mireille Vargas,a,b William Ellis,c Jennifer Keisera,b
Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerlanda; University of Basel, Basel, Switzerlandb;
Department of Chemical Information, Walter Reed Army Institute of Research, Washington, DC, USAc
Chronic Schistosoma mansoni infections lead to severe tissue destruction of the gut wall and liver and can influence drug dispo-
sition. This study aimed to investigate the impact of a chronic S. mansoni infection on the pharmacokinetic (PK) parameters of
two promising antischistosomal lead candidates (mefloquine and enpiroline) in mice. Studies were conducted in two different
mouse cohorts (S. mansoni-infected and uninfected mice) for both drugs. Plasma samples were collected at various time points
after oral treatment (200 mg/kg of body weight) with study drugs. A high-performance liquid chromatography (HPLC) method
was validated to analyze enpiroline and mefloquine in plasma. Livers and intestines were collected from infected animals to de-
termine the onset of action, hepatic shift, and worm burden reduction. Following mefloquine administration, hepatic shifting
and significant worm burden reductions (79.2%) were observed after 72 h. At 1 week posttreatment with enpiroline, the majority
of worms had migrated to the liver and significant worm burden reductions were observed (93.1%). The HPLC method was se-
lective, accurate (87.8 to 111.4%), and precise (<10%) for the analysis of both drugs in plasma samples. The PK profiles revealed
increased values for half-life (t1/2) and area under the concentration-time curve (AUC) for both drugs in infected animals com-
pared to the t1/2 and AUC values in uninfected animals. Considerable changes were observed for mefloquine, with a 5-fold in-
crease of t1/2 (182.7 h versus 33.6 h) and 2-fold increase of AUC (1,116,517.8 ng · h/ml versus 522,409.1 ng · h/ml). S. mansoni
infections in mice influence the PK profiles of enpiroline and mefloquine, leading to delayed clearance. Our data confirm that
drug disposition should be carefully studied in schistosomiasis patients.
Schistosomiasis is one of the most important neglected tropicaldiseases (1). Based on the latest estimates, 780 million people
are at risk of an infection with schistosomes, with the majority of
cases in sub-Saharan Africa (2). Schistosomiasis is a chronic dis-
ease caused by the immunological response to eggs trapped in
tissue and organs. For example, in the case of Schistosoma man-
soni, eggs get trapped mainly in the gut wall and liver, leading to
severe tissue destruction, hepatosplenomegaly, periportal liver fi-
brosis, and portal hypertension (3). Treatment with praziquantel
is the mainstay of control and widely used in preventive chemo-
therapy programs (4).
The liver is one of the main organs in charge of drug metabo-
lism, and the gut wall is significantly involved in the absorption
process of drugs (5). It is therefore not surprising that pharmaco-
kinetic (PK) changes occur in patients with schistosomiasis, de-
pending on the extent of disease (6). For example, a study in
Egyptian schistosomiasis patients treated with praziquantel dem-
onstrated that PK parameters increased in proportion to the de-
gree of hepatic insufficiency (7). In addition, PK studies under-
taken with praziquantel in S. mansoni-infected mice documented
elevated plasma levels in infected animals compared to the plasma
levels in noninfected mice. Furthermore, the infection resulted in
significant inhibition of microsomal cytochrome P450 activities
compared with those in noninfected mice (8).
The areas of endemicity of schistosomiasis and some other
infectious diseases, such as malaria and soil-transmitted hel-
minths, overlap geographically (9). Coendemicity, as well as
known similarities of both parasites, such as hemoglobin diges-
tion (10, 11), were the key rationales for in-depth studies on the
potential antischistosomal effects of antimalarials (9). In recent
years, the antimalarial mefloquine emerged as a promising lead
candidate. The drug presented remarkable in vitro and in vivo
activities against major schistosome species (12) and high egg re-
duction rates in combination with artesunate in an exploratory
clinical trial in Schistosoma haematobium-infected school-aged
children (13). Recently, a clinical trial in pregnant malaria-in-
fected women revealed a positive effect of mefloquine on S.
haematobium coinfections (14). A population PK study of meflo-
quine observed altered PK profiles in malaria-infected persons
compared to the PK profiles in uninfected people (P. Olliaro, per-
sonal communication). Nevertheless, the impact of a schistosome
infection on the drug disposition of mefloquine has not been stud-
ied to date.
The aim of the present study was to investigate the PK param-
eters of mefloquine and enpiroline in the chronic S. mansoni in-
fection mouse model. Enpiroline was included in this study since
recent in vitro and in vivo studies on mefloquine-related aryl-
methanols identified enpiroline as a promising lead candidate
with excellent activity on both S. mansoni and S. haematobium
(12). Drug plasma levels were analyzed between 1 and 168 h after
oral treatment with mefloquine and enpiroline. For that purpose,
we adapted a previously established high-performance liquid
chromatography (HPLC)-UV method (15), revalidated the
method for mouse plasma samples, and expanded it for the quan-
Received 27 May 2013 Returned for modification 18 June 2013
Accepted 1 July 2013
Published ahead of print 8 July 2013
Address correspondence to Jennifer Keiser, jennifer.keiser@unibas.ch.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.01129-13
4506 aac.asm.org Antimicrobial Agents and Chemotherapy p. 4506–4511 September 2013 Volume 57 Number 9
tification of enpiroline. Finally, we determined the onset of action
of both drugs following administration to infected animals.
MATERIALS AND METHODS
Drugs and chemicals. Mefloquine {[2,8-bis(trifluoromethyl)quinolin-4-
yl](-piperidin-2-yl)methanol} was kindly provided by Cilag AG (Switzer-
land). Two mefloquine metabolites, one a human metabolite (Ro 21-
5104) and one an animal metabolite (Ro 14-0518), were gifts of
Hoffmann-La Roche (Switzerland). The Walter Reed Army Institute of
Research (Silver Spring, MD) kindly provided us with enpiroline [threo-
-(2-piperidyl)-2-trifluoromethyl-6-(4-trifluoromethylphenyl)-4-pyri-
dinemethanol]. Chlorpromazine [2-chlor-10-(3-dimethylaminopropyl)
phenothiazin] was purchased from Sigma-Aldrich (Switzerland). Meflo-
quine and enpiroline were dissolved in dimethyl sulfoxide (DMSO) and
chlorpromazine in ethanol (10 mg/ml stock solutions). All analytes are
depicted in Fig. 1. Methanol (Sigma-Aldrich) and acetonitrile (Biosolve
BV, Netherlands) were purchased in HPLC grade. Monobasic potassium
phosphate and phosphoric acid (85%) were acquired from Sigma-Aldrich
(Switzerland).
Animals and parasites. Animal studies were carried out at the Swiss
Tropical and Public Health Institute (Basel, Switzerland) under protocols
approved by Swiss national and cantonal animal welfare regulations.
Three-week-old (weight, 14 g) female NMRI mice (n  119) (Charles
River, Sulzfeld, Germany) were allowed to adapt in the animal facilities for
1 week under controlled conditions (temperature, ca. 22°C; humidity, ca.
50%; 12-h-light and 12-h-dark cycle; and free access to rodent diet and
water) before infection. Half of the mice (infected cohorts) were subcuta-
neously infected with 100 S. mansoni (Liberian strain) cercariae by follow-
ing the standard procedures of our laboratory. Animals were then left
under controlled conditions for 7 weeks to establish an early-stage chronic
schistosome infection with visible impairment of liver (granulomatous
tissue) and gut (swelling, inflammation). The remainder of the mice (un-
infected cohorts) were likewise kept under controlled conditions for 7
weeks.
Pharmacokinetic studies. Pharmacokinetic studies were conducted
in two different mouse cohorts for both drugs, one cohort being S. man-
soni-infected and the second being noninfected NMRI mice. Oral formu-
lations of enpiroline and mefloquine were prepared 3 h before treatment
as water-based suspensions in 7% (vol/vol) Tween 80 and 3% (vol/vol)
ethanol. Groups of mice (n  3 per group) were treated orally with 200 mg
per kg of body weight of enpiroline or mefloquine by gavage and sacrificed
by the CO2 method at selected time points posttreatment (1, 2, 4, 8, 12, 24,
48, 72, or 168 h). Whole-blood samples of 0.5 to 1 ml were collected by
cardiac puncture of each mouse. Each cohort had untreated control mice
(n  8 infected and n  3 noninfected), and each of the four treatment
arms (infected and noninfected mice treated with mefloquine and in-
fected and noninfected mice treated with enpiroline) consisted of 27 mice
for 3 mice per sampling time point. Blood samples were collected into
lithium-heparin-coated Microtainers (Sarstedt) and centrifuged to obtain
plasma samples, which were stored at 80°C until analysis.
Studies on the onset of antischistosomal action in mice. The onset of
action was determined at different time points following treatment with
single oral doses of enpiroline and mefloquine administered to mice (n 
3 per group). After each PK sampling point (1, 2, 4, 8, 12, 24, 48, 72, or 168
h posttreatment), the liver and gut, including the portal vein and mesen-
terial veins, were dissected from infected mice. Livers were pressed and
examined under the microscope, and all worms were sexed and counted
(16). In addition, worms within the portal vein and mesenterial vein sys-
tem were picked and counted separately as described previously (16). The
worm burdens (average numbers of live worms) of treated mice were
compared to the worm burdens of control (nontreated) animals (average
numbers of live worms), and the reductions of worm burden (reduction
of live worms) calculated for each time point. Furthermore, the onset of
action, visible as the migration of worms from the mesenteric veins to the
liver, was determined based on the distribution of worms (live and dead)
within portal and mesenterial veins and pressed livers (hepatic shift).
HPLC-UV analysis and sample extraction. A validated high-perfor-
mance liquid chromatography analytic method introduced by Lai and
colleagues (15) for mefloquine in human plasma was used. The method
was adapted in order to detect mefloquine and enpiroline simultaneously
under similar conditions. Important validation parameters, such as selec-
tivity, intra- and interday accuracy and precision, bench-top stability, and
extraction recovery were determined according to the bioanalytical
method validation guidance for industry of the Food and Drug Adminis-
tration (FDA) (17).
Plasma samples (100 l) were processed using protein precipitation
with methanol containing an internal standard (IS) (chlorpromazine at a
concentration of 5 g/ml). Each mouse sample was extracted three times
on three different days. Samples were vortex mixed and centrifuged (Ep-
pendorf 5415C centrifuge) at 10,000  g for 10 min. The supernatant was
transferred to a microtube and evaporated to dryness in a Speedvac (Lab-
canco) at 38°C for 2 h. The residue was reconstituted in 100 l acetoni-
trile– 0.05 M KH2PO4 buffer (1:1) solution and transferred to an au-
tosampler vial.
Analyte working solutions were prepared by serial dilution in aceto-
nitrile-KH2PO4 buffer (0.05 M) (1:1) to final concentrations of 4, 8, 20,
40, 80, 200, 400, and 800 g/ml. Calibration curves were established by
diluting analyte working solutions with blank mouse plasma (purchased
from Dunn Technik, Germany) (1:20 in a total volume of 100 l). Each
calibration set consisted of one blank plasma sample (plasma sample pro-
cessed without IS), one zero sample (plasma sample spiked with IS), and 8
calibration samples (0.2, 0.4, 1, 2, 4, 10, 20, and 40 g/ml). The lowest and
highest calibrator corresponded to the lower and upper limit of quantifi-
cation (LLOQ and ULOQ), respectively. The LLOQ was selected as the
minimal concentration in plasma samples that could be analyzed with a
precision of 20% (CV%) and accuracy of between 80% and 120% (sig-
nal/noise ratio of 5:1).
In addition, quality control (QC) samples (n  6) were prepared at
low (0.75 g/ml), medium (7.5 g/ml), and high (30 g/ml) concentra-
tions covering the entire calibration range.
Selectivity was determined by examination of blank mouse plasma
obtained from different origins (noninfected NMRI mice and infected
mice without treatment [n  6 each] and commercially acquired mouse
plasma) for interference by endogenous substances using the above-de-
scribed extraction procedure but without adding the IS working solution.
The accuracy and precision of the method were evaluated by analyzing
quality control (QC) samples (n  6 per concentration). The intra- and
interday accuracy/precision were determined within a single run and be-
tween different assays (n  3), respectively. Freshly prepared calibration
standards were used for the analyses. The precision was calculated using
the coefficient of variation (CV [%]). The accuracy represented the mea-
sured concentration as the fraction of the nominal concentration ex-
pressed as a percentage. A precision of 15% (LLOQ, 20%) and accu-
racy of between 85% and 115% (LLOQ, 80 to 120%) were accepted in our
study.
The relative recoveries of mefloquine and enpiroline were determined
by comparing the absolute peak areas of blank plasma samples spiked
before and after the extraction at 0.75, 7.5, and 30 g/ml (n  5 per
FIG 1 Chemical structures of mefloquine, enpiroline, and chlorpromazine
(internal standard).
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concentration). The matrix effects of mefloquine and enpiroline were
assessed as the ratios of the absolute peak areas of blank plasma samples
spiked after the extraction to the absolute peak areas of the analytes solved
in a mixture of acetonitrile-KH2PO4 buffer (1:1, vol/vol).
Autosampler stability and extended bench-top stability studies were
included in our method validation. QC samples were used to test stabili-
ties under different conditions. Autosampler stability was evaluated by the
analysis of QC samples (n  6 per concentration) over a period of 72 h.
Extended bench-top stability was evaluated after samples were kept under
bench-top conditions for 8 h. The concentrations of these samples were
compared with the concentrations of freshly prepared QC samples. The
drug solutions were considered stable with deviations of not more than
15% and 20% at the LLOQ.
For the HPLC-UV detection, an aliquot (50 l) of each sample was
injected onto an Inertsil 8-3 analytical column (2.1 mm by 30 mm, 3.5
m; GL Sciences, Japan). Separation was carried out using an isocratic
elution method with a mobile phase consisting of 35% methanol, 25%
acetonitrile, and 40% KH2PO4 buffer (0.05 M) adjusted to pH 3.9 with
0.05% phosphoric acid. The flow rate was set at 1 ml/min and increased to
1.5 ml/min from 11 min onwards. UV signals were detected at 284 nm.
The Agilent 1100 series HPLC system (Agilent Technologies, Inc.) con-
sisted of binary pumps, a microvacuum degasser, an analytics autosam-
pler, a column heater (temp, 25°C), and a UV-vis detector.
Pharmacokinetic analysis and statistics. The analytical raw data
(area under the concentration-time curve [AUC]) of the plasma samples
were processed with ChemStation software (Agilent). Average values, as
well as calibration lines and animal data, were calculated using Microsoft
Excel 2007. Statsdirect (Statsdirect Ltd., Altrincham, Cheshire, United
Kingdom) was used to determine whether worm burden reductions were
significant (Kruskal-Wallis test). The mean value from the three animals
at each time point was plotted against time to give plasma concentration-
time profiles. The PK parameters of mefloquine and enpiroline were de-
termined by noncompartmental analysis using WinNonLin (version 5.2,
Pharsight Corporation, USA). The following parameters are presented
here: maximal plasma concentration (Cmax; ng/ml), time to achieve max-
imal plasma concentration (Tmax; h), AUC from 0 to 168 h (AUC0-168;
ng · ml/min), AUC extrapolated to infinity (AUC0-; ng · ml/min), and
terminal elimination half-life (t1/2; h). Tmax and Cmax are the observed
data from the mean concentration time curve. The terminal elimination
rate constant is the first-order rate constant associated with the terminal
elimination phase. It is estimated via linear regression of time versus log
concentration. The extrapolated times and areas after the last data point
are extrapolated to infinity. For any of the AUC calculation methods, the
AUC rule after the last time point is the log rule.
RESULTS
Studies on the onset of antischistosomal action of enpiroline
and mefloquine in mice. We studied the worm distribution from
1 h to 168 h after treatment. Following mefloquine administra-
tion, schistosomes started to migrate into the liver (hepatic shift) 8
to 12 h posttreatment. Approximately half of the worms (live and
dead) were found within the liver 1 to 2 days posttreatment, and
nearly all worms (86.5%) were observed in the liver from day 3
onwards (Fig. 2). A worm burden reduction of 79.2% was calcu-
lated at 72 h posttreatment, while a worm burden reduction of
46.9% was determined for the group of mice (n  3) analyzed at 1
week posttreatment.
Worms shifted into the liver slowly following enpiroline treat-
ment, and an equal distribution between liver and mesenterial
veins was reached 72 h posttreatment. The majority of worms had
migrated to the liver 1 week posttreatment. Enpiroline evolved its
full antischistosomal activity 1 week posttreatment, revealing a
significant worm burden reduction of 93.1%.
Validation of the HPLC-UV method. The calibration curves
of mefloquine and enpiroline were linear from 200 to 40,000
ng/ml mouse plasma (R2  0.999). The applied method was found
to be selective, since there was no interference between the reten-
tion times of analytes and any endogenous substances (signal/
noise ratio of 5:1) or any mefloquine metabolites tested (human
and animal metabolites). The mean extraction recoveries esti-
mated for mefloquine and enpiroline were 76.6% and 71.3%, re-
spectively, and were consistent over the whole calibration line
with a CV of less than 12%. Only minor matrix effects (	20%)
were present (Table 1).
The intraday accuracy estimated for both analytes ranged from
FIG 2 Worm distribution (live and dead) between liver and mesenterial vein system presented over time posttreatment with 200 mg/kg mefloquine (A) or
enpiroline (B).
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87.8% to 111.4%, with a precision of 10%. Interday accuracy
was always within a 90 to 110% margin, with a maximal impreci-
sion of 10.5% (Table 2). The LLOQ value of 200 ng/ml plasma was
determined with interday accuracies of 97.4%  3.8% for meflo-
quine and 113.5%  4.4% for enpiroline.
The results obtained from stability experiments demonstrated
that the samples were stable for increased times under bench-top
conditions (t  8 h) and autosampler conditions (10°C, t  72 h).
Variations of plasma samples following 72 h under autosampler
conditions were below 2.9%, and accuracies ranged from 90.2 to
103.5%. Stability was likewise observed for our samples when left
at room temperature (23 to 25°C) for 8 h.
Disposition of enpiroline and mefloquine in S. mansoni-in-
fected and uninfected mice. The established HPLC-UV method
was used to study the pharmacokinetics of mefloquine and en-
piroline in S. mansoni-infected and noninfected NMRI mice fol-
lowing the administration of a single oral dose of 200 mg/kg me-
floquine or enpiroline. The pharmacokinetic parameters are
summarized in Table 3.
A 2-fold increase of the AUC0- for mefloquine and enpiroline
was observed in S. mansoni-infected mice. The Cmax levels were
increased 30 to 40% within the noninfected cohorts (10,223 ng/ml
versus 7,238 ng/ml for mefloquine [R2  0.94 to 0.98] and 7,641
ng/ml versus 5,746 ng/ml for enpiroline [R2  0.99]). The time to
achieve maximal concentration (Tmax) altered only for enpiroline,
with Tmax being reached 24 h later in the noninfected animals than
in infected mice (24 versus 48 h). The half-lives (t1/2) of meflo-
quine and enpiroline were elevated 5- and 2.5-fold, respectively
(182.7 h versus 33.6 h for mefloquine and 182.1 h versus 72 h for
enpiroline), in the infected population. The plasma concentra-
tion-time profiles of both drugs in infected and uninfected mice
are presented in Fig. 3.
DISCUSSION
Chronic S. mansoni infections cause substantial pathological and
physiological changes in infected patients, leading to clinical
symptoms such as abdominal pain, diarrhea, blood in the stool,
and finally, liver cirrhosis and portal hypertension (18).
The liver and gut, which are affected the most by S. mansoni
infection, play important roles in drug metabolism and disposi-
tion (3, 19). Changes in the absorption, distribution, metabolism,
and elimination of orally applied drugs are therefore very likely in
S. mansoni-infected individuals. An altered drug disposition has
been shown in several clinical trials in patients with schistosomi-
asis (6, 7).
In the past few years, drug metabolism and PK studies have
increasingly been integrated into early stages of the drug discovery
process. However, in the field of schistosomiasis, few studies have
been carried out to date elucidating the pharmacokinetic/phar-
macodynamic (PK/PD) relationships and studying the influence
of the parasitic infection on drug disposition. It was therefore our
aim to investigate the PK properties of the two antimalarials me-
floquine and enpiroline in S. mansoni-infected and uninfected
animals.
We successfully adapted an analytical HPLC-UV method,
originally used to determine artesunate, its active metabolite di-
hydroartemisinin, and mefloquine in human plasma (15), to an-
alyze enpiroline and mefloquine in mouse plasma. The accuracy,
precision, and sensitivity values documented for our analytical
method were similar to those obtained in the original work.
TABLE 1 Relative recovery and matrix effect of mefloquine and
















Mefloquine 750 78.4 76.6  7.9 86.2 83.9  7.1
7,500 72.9 77.5
30,000 78.3 88.1
Enpiroline 750 66.3 71.3  12 90.7 84.3  11.1
7,500 69.8 75.2
30,000 77.9 87.0
a n  5 samples.

















Mefloquine (linear, R2  0.9995) 750 835.3 1.8 111.4 732.0 9.5 97.6
7,500 6,779.9 2.9 90.4 7,625.3 8.9 101.7
30,000 29,129.3 2.0 97.1 31,222.4 6.4 104.1
Enpiroline (linear, R2  0.9996) 750 816.9 5.0 108.9 797.2 8.9 106.3
7,500 6,584.6 5.4 87.8 7,762.6 10.5 103.5
30,000 28,809.1 2.2 96.0 31,905.2 8.0 106.4
a Intraday values are the mean values of 6 samples. The results of one representative experiment are shown. Interday values are the mean values of 3 independent sets of
experiments. RSD, relative standard deviation.
TABLE 3 Pharmacokinetic parameters of mefloquine and enpiroline
following oral administration to mice infected or not infected with S.
mansoni
Parameter







t1/2 (h) 182.7 33.6 182.1 72.0
AUC0-168 (ng · h/ml) 567,845.5 503,623.5 819,557.5 859,603
AUC0- (ng · h/ml) 1,116,517.8 522,409.1 1,790,287.1 1,107,982.3
Cmax (ng/ml) 7,238 10,223 5,746 7,641
Tmax (h) 12 12 24 48
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The speed of onset of action represents a key pharmacody-
namic parameter. We determined the hepatic shift (a well-de-
scribed parameter in antischistosomal drug discovery), which
monitors the forced migration of schistosomes to the liver after
treatment with active drugs (20). Interestingly, the hepatic shift of
all worms started rather late, only 72 h posttreatment for meflo-
quine and 168 h following drug administration for enpiroline. The
hepatic shift of mefloquine observed in our study was comparable
to those in two previous studies in S. mansoni-infected mice using
a single oral dose of 400 mg/kg (21, 22). Mefloquine acts slightly
faster in Schistosoma japonicum-infected mice (22, 23). The slow
onset of action of mefloquine on schistosomes in vivo has been
reported in other studies (23). In contrast, praziquantel acts much
faster; the hepatic shift was already completed 30 min after oral
drug administration (unpublished observations), which might be
explained by the drug’s action on the muscles of schistosomes. In
addition, in vivo studies showed that extensive structural changes
to worms occurred within 15 min after treatment and adult
worms died within 24 h following treatment with praziquantel
(21, 24).
Interestingly, the majority of worms exposed to mefloquine
were still not affected at 7 days (reduction in worm burden,
46.9%) posttreatment in our study. On the other hand, previous
studies presented worm burden reductions of 74.1% already at 1
week posttreatment with mefloquine (400 mg/kg), and a worm
burden reduction of 72.3% at 2 weeks posttreatment was observed
for the dosage of 200 mg/kg (22). These differences in worm bur-
den reductions might be explained by the rather small groups of
three mice per time point in our study setup. Additionally, the
speed of action of the 200 mg/kg dosage might be slower.
The rather late onsets of action might correlate with the long
half-lives determined for mefloquine (t1/2, 182.7 h) and enpiroline
(t1/2, 182.1 h) in infected animals, which are increased as much as
2.5- to 5-fold compared to those in noninfected animals. A previ-
ous PK study with mefloquine in uninfected mice revealed a half-
life of 17 h after oral treatment with 8 to 10 mg/kg, which is in a
range similar to that described from our estimation of 33.6 h (25).
However, it is important to emphasize that a rather small sample
size was used in the present work and interindividual variations
between the animals are high. Furthermore, the estimated AUC is
2-fold higher in infected animals than in noninfected mice for
both drugs. The slow clearance of both drugs might be attributed
to a decreased activity of the cytochrome P450 enzyme system
caused by the S. mansoni infection (8). It is known that the AUC
and the elimination half-life of mefloquine in humans are signif-
icantly increased by inhibition of CYP3A4 with inhibitors (e.g.,
ketoconazole) (Lariam information leaflet). Surprisingly, both
drugs presented rather decreased maximal plasma concentrations
(Cmax) in infected mice. The heavy inflammation of the gut wall
that was observed microscopically might result in decreased drug
absorption, which could be an explanation for this finding. It is
interesting to note that, contrary to our findings, increased Cmax
values were determined for praziquantel in infected rodents (8).
Mefloquine presented plasma concentrations above the IC50
(half-maximal inhibitory concentration) value determined in
vitro (4.7  2.8 g/ml at 24 h postexposure) for approximately 32
h (12). Interestingly, the plasma levels of enpiroline did not reach
the IC50 determined at 24 h in vitro (7.4  2.7 g/ml). However,
enpiroline is a slow-acting drug in vitro, presenting an IC50 of 3.1
g/ml after 72 h of drug exposure (12). The plasma level remained
above this concentration for up to 150 h. Since Cmax levels are
reached much earlier (12 h for mefloquine and 24 h for enpiro-
line) than the onset of action (24 to 72 h for mefloquine and 168 h
for enpiroline), one can speculate that the antischistosomal activ-
ities of both drugs are AUC rather than Cmax driven. However,
further rigorous PK/PD studies are required to strengthen our
hypothesis.
In conclusion, we showed that an S. mansoni infection triggers
considerable changes in the drug disposition of mefloquine and
enpiroline. Pharmacokinetic studies with antischistosomal lead
candidates in infected animals should be integrated early in the
drug discovery process. In addition, PK studies should be con-
ducted in S. mansoni- and S. haematobium-infected children, the
key target group of preventive chemotherapy, since children de-
pend greatly on safe, efficacious, and controlled dosage regimens.
Our findings might be of public health relevance, since meflo-
quine is widely used in areas where schistosome infections are
common. Overdosing might occur and lead to toxic adverse
events, which might be of relevance in light of the reported neu-
rotoxicity of mefloquine (26). Furthermore, influences on the
pharmacokinetic profiles of antimalarials could lead to prolonged
plasma levels beneath the minimal inhibition concentration and,
hence, result in suboptimal dosing and selection for drug-resistant
parasites. Therefore, in-depth studies should also be conducted
with antimalarials in patients coinfected with S. mansoni and Plas-
modium falciparum.
FIG 3 Mean plasma concentration-time profiles of mefloquine (A) and enpiroline (B) after oral administration of drug at 200 mg/kg to 3 mice per time point
for either infected or noninfected animals. Error bars show standard deviations.
Ingram et al.
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